Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/27/2025 | $36.00 | Buy | Lake Street |
| 7/22/2025 | $29.00 | Buy | Roth Capital |
| 2/20/2025 | $38.00 | Buy | B. Riley Securities |
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that on September 9, 2025, its Board of Directors authorized Electromed to repurchase up to $10.0 million of Electromed common stock. This follows the exhaustion of Electromed's most recent share repurchase authorization in the fourth quarter of fiscal 2025, as previously reported. The timing and amount of share repurchases, if any, will be determined by management based on its evaluation of market conditions and other considerations. Repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades
Record quarterly and annual revenues and operating income, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2025") and full year ended June 30, 2025 ("FY 2025"). Q4 FY 2025 Company Highlights Net revenue increased 17.3% to a record $17.4 million in Q4 FY 2025, from $14.8 million in the fourth quarter of the prior fiscal year. Operating income was a record $3.0 million, a 30.2% increase from the fourth quarter of the prior fiscal year. Net income was $2.2 million, or $0.25 p
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202
Lake Street resumed coverage of Electromed with a rating of Buy and set a new price target of $36.00
Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00
B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
8-K - Electromed, Inc. (0001488917) (Filer)
10-K - Electromed, Inc. (0001488917) (Filer)
8-K - Electromed, Inc. (0001488917) (Filer)
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off
Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing
Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle
Record quarterly and annual revenues and operating income, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2025") and full year ended June 30, 2025 ("FY 2025"). Q4 FY 2025 Company Highlights Net revenue increased 17.3% to a record $17.4 million in Q4 FY 2025, from $14.8 million in the fourth quarter of the prior fiscal year. Operating income was a record $3.0 million, a 30.2% increase from the fourth quarter of the prior fiscal year. Net income was $2.2 million, or $0.25 p
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 third quarter ended March 31, 2025, on May 13, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q3 Fiscal 2025
SC 13D/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)